IDEXX Laboratories, Inc. $IDXX Holdings Raised by Congress Asset Management Co.

Congress Asset Management Co. increased its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 9,894.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 153,908 shares of the company’s stock after purchasing an additional 152,368 shares during the quarter. Congress Asset Management Co. owned 0.19% of IDEXX Laboratories worth $104,123,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in IDXX. EverSource Wealth Advisors LLC increased its stake in IDEXX Laboratories by 2.5% during the third quarter. EverSource Wealth Advisors LLC now owns 621 shares of the company’s stock valued at $397,000 after purchasing an additional 15 shares during the last quarter. MassMutual Private Wealth & Trust FSB lifted its position in shares of IDEXX Laboratories by 4.4% in the 3rd quarter. MassMutual Private Wealth & Trust FSB now owns 380 shares of the company’s stock worth $243,000 after buying an additional 16 shares during the last quarter. Moss Adams Wealth Advisors LLC boosted its holdings in shares of IDEXX Laboratories by 3.3% in the 3rd quarter. Moss Adams Wealth Advisors LLC now owns 528 shares of the company’s stock valued at $337,000 after buying an additional 17 shares during the period. CWA Asset Management Group LLC boosted its holdings in shares of IDEXX Laboratories by 3.5% in the 4th quarter. CWA Asset Management Group LLC now owns 509 shares of the company’s stock valued at $344,000 after buying an additional 17 shares during the period. Finally, Private Trust Co. NA grew its position in shares of IDEXX Laboratories by 9.4% during the 3rd quarter. Private Trust Co. NA now owns 209 shares of the company’s stock valued at $134,000 after buying an additional 18 shares during the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

Insider Activity at IDEXX Laboratories

In other news, EVP Nimrata Hunt sold 2,693 shares of IDEXX Laboratories stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $661.54, for a total transaction of $1,781,527.22. Following the transaction, the executive vice president directly owned 19,899 shares in the company, valued at approximately $13,163,984.46. This trade represents a 11.92% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Jonathan Jay Mazelsky sold 23,326 shares of the business’s stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $657.55, for a total value of $15,338,011.30. Following the completion of the sale, the chief executive officer directly owned 83,606 shares in the company, valued at $54,975,125.30. This represents a 21.81% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 45,957 shares of company stock worth $29,862,109 in the last quarter. Company insiders own 0.98% of the company’s stock.

IDEXX Laboratories Trading Up 0.2%

Shares of NASDAQ:IDXX opened at $578.51 on Tuesday. The company has a 50 day moving average of $642.81 and a 200-day moving average of $664.28. The company has a current ratio of 1.23, a quick ratio of 0.90 and a debt-to-equity ratio of 0.23. The firm has a market cap of $46.00 billion, a P/E ratio of 44.26, a P/E/G ratio of 3.50 and a beta of 1.66. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Monday, February 2nd. The company reported $2.92 EPS for the quarter, missing analysts’ consensus estimates of $2.93 by ($0.01). IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The company had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. During the same quarter in the prior year, the business earned $2.53 EPS. IDEXX Laboratories’s revenue was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. As a group, analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on IDXX shares. Weiss Ratings lowered shares of IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, January 29th. Piper Sandler lowered their target price on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a report on Monday, February 9th. Wall Street Zen cut IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 28th. UBS Group cut their price target on IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating on the stock in a report on Tuesday, February 3rd. Finally, BTIG Research reduced their price objective on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a research report on Tuesday, February 3rd. Seven equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, IDEXX Laboratories has an average rating of “Moderate Buy” and an average price target of $783.33.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.